MIURA MASATOMO 三浦昌朋

… Alternative Names

MIURA Masatomo 三浦昌朋

Less

Researcher Number	30265194
Other IDs
Affiliation (Current)	2025: 秋田大学, 医学系研究科, 教授
Affiliation (based on the past Project Information) *help	2024: 秋田大学, 医学系研究科, 教授 2021 – 2022: 秋田大学, 医学系研究科, 教授 2018 – 2020: 秋田大学, 医学部附属病院, 教授 2012 – 2017: 秋田大学, 医学部, 教授 2009 – 2012: 秋田大学, 医学部, 准教授 2008: 秋田大学, 医学部, 講師
Review Section/Research Field	Principal Investigator Medical pharmacy / Basic Section 47060:Clinical pharmacy-related Except Principal Investigator Urology / Basic Section 54010:Hematology and medical oncology-related / Medical pharmacy / Hematology
Keywords	Principal Investigator 血中濃度 / 分子標的治療薬 / 遺伝子多型 / 分子標的抗がん剤 / バイオマーカー / 個別化治療 / TDM / 副作用 / 投与量 / ボスチニブ … More / レンバチニブ / 高齢者 / 抗がん剤 / 精密医療 / 個別化療法 … More Except Principal Investigator 薬物動態 / 腎移植 / 遺伝子多型 / 免疫抑制薬 / タクロリムス / 血中濃度 / 個別投与量設計 / 線維増生 / 薬剤耐性 / チロシンキナーゼ阻害薬 / 慢性骨髄性白血病 / 膠原病 / 薬物動態学的相互作用 / イトラコナゾール / エベロリムス / TDM / 骨髄移植 / CYP3A5遺伝子多型 / 腎線維化 / ドナー特異抗体 / CYP3A5 / 繊維増生 / 拒絶反応 / 画像解析 / 薬理遺伝学 / 薬物濃度 / BIM / SNP / 薬物輸送蛋白 / T/Nk細胞プロファイリング / 制御性T細胞 / 薬物トランスポーター / NK細胞 / T細胞 / レナリドミド / 治療効果 / 多発性骨髄腫 / 線維化 / 移植・再生医療 / 移植腎機能 / 個別医療設計 / 線維増殖 / カルシニュリン阻害薬 / 臨床因子 / 移植腎線維増生 / 急性拒絶 / 画像解析装置 / 移植後糖尿病 / 慢性移植腎症 Less

Development of the new treatment technique utilizing the biomarkers of the molecular target drugs with the VEGFR2 inhibitory actionPrincipal Investigator
- Principal Investigator
  
  三浦昌朋
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Akita University
TKI抵抗性CMLに対するエキソーム解析とFRET解析の統合による個別化治療の可能性
- Principal Investigator
  
  高橋直人
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Akita University
Development of the treatment strategy for molecular target anticancer drugs to avoid serious side effectsPrincipal Investigator
- Principal Investigator
  
  MIURA MASATOMO
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 47060:Clinical pharmacy-related
- Research Institution
  Akita University
Personalized medicine of oral molecular-targeted anticancer drugs for elderly patientsPrincipal Investigator
- Principal Investigator
  
  Miura Masatomo
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Akita University
Influence of tacrolimus initial doing strategy based on the CYP3A5 polymorphisms on quantitative interstitial fibrosis, rejection rate, and long-term graft function in kidney transplant recipients.
- Principal Investigator
  
  Satoh Shigeru
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Akita University
Development of a new treatment strategy using TDM for next generation anticancer drugPrincipal Investigator
- Principal Investigator
  
  Miura Masatomo
- Project Period (FY)
  2014 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Akita University
Therapeutic drug management of the novel agents for multiple myeloma
- Principal Investigator
  
  Takahashi Naoto
- Project Period (FY)
  2014 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Hematology
- Research Institution
  Akita University
Do patients taking tacrolimus need to undergo CYP3A5 genotyping along with blood concentration monitoring?
- Principal Investigator
  
  Niioka Takenori
- Project Period (FY)
  2014 – 2017
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Akita University
Therapeutic drug management of tyrosine kinase inhibitorPrincipal Investigator
- Principal Investigator
  
  MIURA MASATOMO
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Akita University
Factors Increasing Interstitial Fibrosis and Its Reduction with Personalized Dosing of Immunosuppressive Drugs after Kidney Transplantation
- Principal Investigator
  
  SATOH Shigeru
- Project Period (FY)
  2011 – 2013
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Akita University
Clinical and Genomic Risk Factors for Early Onset of Chronic Allograft Nephropathy
- Principal Investigator
  
  SATOH Shigeru
- Project Period (FY)
  2008 – 2010
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Akita University

[Book] 診断と治療のABC，慢性骨髄性白血病・骨髄増殖性腫瘍2016
- Author(s)
  三浦昌朋
- Total Pages
  2
- Publisher
  最新医学社
- Data Source
  KAKENHI-PROJECT-26460188
[Book] ミコフェノール酸モフェチル.腎疾患治療マニュアル 2013-2014 腎と透析2013
- Author(s)
  佐藤滋, 三浦昌朋((編)腎と透析編集委員会)
- Publisher
  東京医学社, 東京(74 増刊号)
- Data Source
  KAKENHI-PROJECT-23592378
[Book] Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients. Myeloid Leukemia–Clinical Diagnosis and Treatment2011
- Author(s)
  Takahashi, N and Miura, M
- Publisher
  INTECH, Croatia
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients.2023
- Author(s)
  Fukushi Y, Akamine Y, Abumiya M, Tozawa N, Yamashita T, Nara M, Kameoka Y, Takahashi N, Miura M.
- Journal Title
  
  Br J Clin Pharmacol.
  
  Volume: 89(5) Issue: 5 Pages: 1695-1700
- DOI
  10.1111/bcp.15650
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22H04291, KAKENHI-PROJECT-20K07150
[Journal Article] Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy2022
- Author(s)
  Fukuda N, Akamine Y, Abumiya M, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 89(5) Issue: 5 Pages: 609-616
- DOI
  10.1007/s00280-022-04419-1
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy2022
- Author(s)
  Fujita K, Motoyama S, Sato Y, Wakita A, Nagaki Y, Minamiya Y, Miura M.
- Journal Title
  
  Esophagus.
  
  Volume: 19 Issue: 1 Pages: 146-152
- DOI
  10.1007/s10388-021-00865-7
- NAID
  40022800671
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer2022
- Author(s)
  Yokota Hayato、Sato Kazuhiro、Sakamoto Sho、Okuda Yuji、Fukuda Natsuki、Asano Mariko、Takeda Masahide、Nakayama Katsutoshi、Miura Masatomo
- Journal Title
  
  Investigational New Drugs
  
  Volume: 40 Issue: 6 Pages: 1254-1262
- DOI
  10.1007/s10637-022-01304-9
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K08149, KAKENHI-PROJECT-21K08434, KAKENHI-PROJECT-22H04281, KAKENHI-PROJECT-18K08188, KAKENHI-PROJECT-20K07150
[Journal Article] Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer2022
- Author(s)
  Kumagai M, Nagahama M, Akamine Y, Ozeki T, Suzuki A, Sugino K, Ito K, Miura M.
- Journal Title
  
  Cancer Diagn Progn
  
  Volume: 2(3) Issue: 3 Pages: 336-344
- DOI
  10.21873/cdp.10114
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia2021
- Author(s)
  Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi H, Miyazaki Y, Nishikawa H, Takahashi N
- Journal Title
  
  Cancers
  
  Volume: 13 Issue: 23 Pages: 5904-5904
- DOI
  10.3390/cancers13235904
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17H06162, KAKENHI-PROJECT-20K07150
[Journal Article] Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL2021
- Author(s)
  Kawano N, Kimura S, Miura M, Tochigi T, Nakaike T, Yamashita K, Mashiba K, Kikuchi I, Takahashi N.
- Journal Title
  
  Int J Hematol.
  
  Volume: 114 Issue: 4 Pages: 509-516
- DOI
  10.1007/s12185-021-03186-8
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial2021
- Author(s)
  Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Sakamoto J, Kimura S.
- Journal Title
  
  Lancet Haematol
  
  Volume: 8 Issue: 12 Pages: e902-e911
- DOI
  10.1016/s2352-3026(21)00333-1
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08861, KAKENHI-PROJECT-20K07150, KAKENHI-PROJECT-20K08756, KAKENHI-PROJECT-21K16245
[Journal Article] Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy2021
- Author(s)
  Fujita Kazuma、Motoyama Satoru、Sato Yusuke、Wakita Akiyuki、Nagaki Yushi、Minamiya Yoshihiro、Miura Masatomo
- Journal Title
  
  Medical Oncology
  
  Volume: 38 Issue: 1 Pages: 6-6
- DOI
  10.1007/s12032-020-01450-1
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20H01096, KAKENHI-PROJECT-20K07150
[Journal Article] Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy2021
- Author(s)
  Abumiya M, Takahashi N, Takahashi S, Yoshioka T, Kameoka Y, Miura M.
- Journal Title
  
  Sci Rep
  
  Volume: 11 Issue: 1 Pages: 6362-6362
- DOI
  10.1038/s41598-021-85757-7
- NAID
  120007172092
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07150, KAKENHI-PROJECT-21H04171
[Journal Article] Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolemia in patients with chronic myeloid leukemia2021
- Author(s)
  Abumiya M, Akamine Y, Sato S, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.
- Journal Title
  
  J Clin Pharm Ther
  
  Volume: 46 Issue: 2 Pages: 382-387
- DOI
  10.1111/jcpt.13294
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute2021
- Author(s)
  Kidoguchi K, Ureshino H, Kizuka-Sano H, Yamaguchi K, Katsuya H, Kubota Y, Ando T, Miura M, Takahashi N, Kimura S.
- Journal Title
  
  Int J Hematol.
  
  Volume: 114 Issue: 2 Pages: 199-204
- DOI
  10.1007/s12185-021-03156-0
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150, KAKENHI-PROJECT-21K16245
[Journal Article] Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer2021
- Author(s)
  Yokota Hayato、Sato Kazuhiro、Sakamoto Sho、Okuda Yuji、Asano Mariko、Takeda Masahide、Nakayama Katsutoshi、Miura Masatomo
- Journal Title
  
  Biology
  
  Volume: 10 Issue: 10 Pages: 1054-1054
- DOI
  10.3390/biology10101054
- NAID
  120007172095
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21H04217, KAKENHI-PROJECT-18K08188, KAKENHI-PROJECT-20K07150, KAKENHI-PROJECT-21K08149, KAKENHI-PROJECT-21K08434
[Journal Article] Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance2021
- Author(s)
  Abumiya M, Takahashi N, Yoshioka T, Kameoka Y, Miura M
- Journal Title
  
  J Clin Pharm Ther
  
  Volume: 46 Issue: 1 Pages: 219-222
- DOI
  10.1111/jcpt.13257
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration2021
- Author(s)
  Ito F, Miura M, Fujioka Y, Abumiya M, Kobayashi T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N.
- Journal Title
  
  Int J Hematol
  
  Volume: 113 Issue: 1 Pages: 100-105
- DOI
  10.1007/s12185-020-03000-x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease.2020
- Author(s)
  Mori J, Oshima K, Tanimoto T, Ishizuka H, Kimura S, Miura M, Takahashi N.
- Journal Title
  
  Int J Hematol
  
  Volume: - Issue: 1 Pages: 115-117
- DOI
  10.1007/s12185-020-02846-5
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib2020
- Author(s)
  Sakamoto Sho、Sato Kazuhiro、Takita Yuri、Izumiya Yuka、Kumagai Naho、Sudo Kazuhisa、Hasegawa Yukiyasu、Yokota Hayato、Akamine Yumiko、Okuda Yuji、Asano Mariko、Takeda Masahide、Sano Masaaki、Miura Masatomo、Nakayama Katsutoshi
- Journal Title
  
  Investigational New Drugs
  
  Volume: 38 Issue: 6 Pages: 1687-1695
- DOI
  10.1007/s10637-020-00946-x
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09602, KAKENHI-PROJECT-17K09993, KAKENHI-PROJECT-18K08188, KAKENHI-PROJECT-18K10738, KAKENHI-PROJECT-20K07150
[Journal Article] 新規TDM対象薬への対応と展望2020
- Author(s)
  三浦昌朋
- Journal Title
  
  日本病院薬剤師会雑誌
  
  Volume: 56 Pages: 977-981
- NAID
  40022351637
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07150
[Journal Article] Effects ofSTAT3polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer2020
- Author(s)
  Yokota Hayato、Sato Kazuhiro、Sakamoto Sho、Okuda Yuji、Asano Mariko、Takeda Masahide、Nakayama Katsutoshi、Miura Masatomo
- Journal Title
  
  Journal of Clinical Pharmacy and Therapeutics
  
  Volume: 45 Issue: 4 Pages: 652-659
- DOI
  10.1111/jcpt.13173
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09602, KAKENHI-PROJECT-17K09993, KAKENHI-PROJECT-18K08188, KAKENHI-PROJECT-20K07150
[Journal Article] The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia2020
- Author(s)
  Taniguchi Y, Takahashi N, Miura M, Hirase C, Sueda S, Espinoza JL, Rai S, Nakayama S, Serizawa K, Kumode T, Watatani Y, Morita Y, Tanaka H, Matsumura I.
- Journal Title
  
  Intern. Med.
  
  Volume: 59 Issue: 21 Pages: 2745-2749
- DOI
  10.2169/internalmedicine.4871-20
- NAID
  130007934222
- ISSN
  0918-2918, 1349-7235
- Year and Date
  2020-11-01
- Language
  English
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07150, KAKENHI-PROJECT-20K08743, KAKENHI-PROJECT-18K08375
[Journal Article] Personalized medicine for oral molecular-targeted anticancer drugs2019
- Author(s)
  Miura M.
- Journal Title
  
  Folia Pharmacologica Japonica
  
  Volume: 153 Issue: 2 Pages: 73-78
- DOI
  10.1254/fpj.153.73
- NAID
  130007596166
- ISSN
  0015-5691, 1347-8397
- Language
  Japanese
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.2019
- Author(s)
  Nagahama M, Ozeki T, Suzuki A, Sugino K, Niioka T, Ito K, Miura M.
- Journal Title
  
  Med Oncol.
  
  Volume: 36(5) Issue: 5 Pages: 39-39
- DOI
  10.1007/s12032-019-1263-3
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype.2019
- Author(s)
  Yagishita H, Minami S, Akamine Y, Kato S, Iijima K, Miura M.
- Journal Title
  
  J Clin Pharm Ther
  
  Volume: 44 Issue: 6 Pages: 977-980
- DOI
  10.1111/jcpt.13030
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update2019
- Author(s)
  Miura M, Takahashi N.
- Journal Title
  
  Rinsho Ketsueki
  
  Volume: 60 Issue: 9 Pages: 1140-1147
- DOI
  10.11406/rinketsu.60.1140
- NAID
  130007724692
- ISSN
  0485-1439, 1882-0824
- Language
  Japanese
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.2019
- Author(s)
  Ozeki T, Nagahama M, Fujita K, Suzuki A, Sugino K, Ito K, Miura M.
- Journal Title
  
  Sci Rep.
  
  Volume: 9(1) Issue: 1 Pages: 5404-5404
- DOI
  10.1038/s41598-019-41820-y
- NAID
  120007172093
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia2018
- Author(s)
  Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y and Takahashi N
- Journal Title
  
  Experimental Hematology & Oncology
  
  Volume: 印刷中 Issue: 1 Pages: 9-9
- DOI
  10.1186/s40164-018-0101-1
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.2018
- Author(s)
  Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.
- Journal Title
  
  Med Oncol. .
  
  Volume: ;35(6） Issue: 6 Pages: 90-90
- DOI
  10.1007/s12032-018-1146-z
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitianl fibrosis and long-term graft function in kidney transplant recipients.2018
- Author(s)
  Komine N, Satoh S, Saito M, Numakura K, Inoue T, Tsuruta H, Narita S, Komatsuda A, Nanjo H, Kagaya H, Niioka T, Miura M, Mitobe Y, Habuchi T.
- Journal Title
  
  Int Immunopharmacol
  
  Volume: 58 Pages: 57-63
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K10636
[Journal Article] Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.2018
- Author(s)
  Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T.
- Journal Title
  
  Med Oncol.
  
  Volume: 35(51) Issue: 4 Pages: 51-58
- DOI
  10.1007/s12032-018-1113-8
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K16773, KAKENHI-PROJECT-17K08408, KAKENHI-PROJECT-15K10573, KAKENHI-PROJECT-16H02679
[Journal Article] Prediction of tacrolimus exposure by CYP3A5 genotype and exposure of co-administrated everolimus in Japanes renal transplant recipients.2018
- Author(s)
  Kagaya H, Niioka T, Saito M, Inoue M, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.
- Journal Title
  
  Int J Mol Sci
  
  Volume: 19
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K10636
[Journal Article] Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide.2018
- Author(s)
  Kobayashi T, Miura M, Niioka T, Abumiya M, Ito F, Kobayashi I, Ikeda S, Yoshioka T, Kameoka Y, Takahashi N.
- Journal Title
  
  Ther Drug Monit.
  
  Volume: 印刷中 Issue: 3 Pages: 301-309
- DOI
  10.1097/ftd.0000000000000499
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.2018
- Author(s)
  Kagaya H, Niioka T, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.
- Journal Title
  
  Int J Mol Sci
  
  Volume: 19 Issue: 3 Pages: 882-882
- DOI
  10.3390/ijms19030882
- NAID
  120007172094
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26460189, KAKENHI-PROJECT-18H00362
[Journal Article] Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients.2018
- Author(s)
  Abumiya M, Miura M, Takahashi N.
- Journal Title
  
  Leuk Res
  
  Volume: 64 Pages: 42-45
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Quantification of intersititial fibrosis in renal allografts and clinical correlates of long-term graft function.2017
- Author(s)
  Nara M, Komatsuda, Numakura K, Saito M, Inoue T, Niioka T, Miura M, Mitober Y, Okuyama S, Takahashi N, Habuchi T, Satoh S
- Journal Title
  
  Am J Nephrol
  
  Volume: 46 Pages: 187-194
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K10636
[Journal Article] Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.2017
- Author(s)
  Numakura K, Tsuchiya N, Kagaya H, Takahashi M, Tsuruta H, Inoue T, Narita S, Huang M, Satoh S, Niioka T, Miura M, Habuchi T.
- Journal Title
  
  Anticancer Drugs.
  
  Volume: 28(1) Pages: 97-103
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] 分子標的抗がん剤の個別化医療　血中濃度測定と臨床応用2017
- Author(s)
  三浦昌朋
- Journal Title
  
  日本病院薬剤師会雑誌
  
  Volume: 53 Pages: 1479-1483
- NAID
  40021410355
- Data Source
  KAKENHI-PROJECT-17K08408
[Journal Article] Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanes renal transplant recipients receiving different tacrolimus formulations.2017
- Author(s)
  Niioka, T, Kagaya H, Saito S, Inoue T, Numakura K, Yamamoto R, Habuch T, Satoh S, Miura M.
- Journal Title
  
  Clin Exp Nephrol
  
  Volume: 21 Pages: 787-796
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K10636
[Journal Article] Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.2017
- Author(s)
  Okuda Y, Sato K, Sudo K, Hasegawa Y, Asano M, Miura H, Takeda M, Sano M, Watanabe H, Kobayashi H, Niioka T, Miura M, Ito H.
- Journal Title
  
  Cancer Chemother Pharmacol.
  
  Volume: in press
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis2016
- Author(s)
  Takahiro Kobayashi, Takenori Niioka, Masatomo Miura, Naoto Takahashi
- Journal Title
  
  Ann Hematol
  
  Volume: 95(12) Issue: 12 Pages: 2087-2088
- DOI
  10.1007/s00277-016-2809-5
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26461414
[Journal Article] Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.2016
- Author(s)
  Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.
- Journal Title
  
  Int J Urol.
  
  Volume: in press Issue: 6 Pages: 484-490
- DOI
  10.1111/iju.13081
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460189
[Journal Article] Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods.2016
- Author(s)
  Miura M, Takahashi N.
- Journal Title
  
  Drug Metab Pharmacokinet.
  
  Volume: 31(1) Issue: 1 Pages: 12-20
- DOI
  10.1016/j.dmpk.2015.09.002
- NAID
  50014431236
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] Quantitative determination of regorafenib and its two major metabolites in human plasma with high-performance liquid chromatography and ultraviolet detection.2016
- Author(s)
  Fujita K, Miura M, Shibata H.
- Journal Title
  
  Biomed Chromatogr.
  
  Volume: 30(10) Issue: 10 Pages: 1611-7
- DOI
  10.1002/bmc.3730
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.2016
- Author(s)
  Kobayashi T, Niioka T, Miura M, Takahashi N.
- Journal Title
  
  Ann Hematol.
  
  Volume: 95(12) Pages: 2087-2088
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.2016
- Author(s)
  Kobayashi H, Sato K, Niioka T, Takeda M, Okuda Y, Asano M, Ito H, Miura M.
- Journal Title
  
  Med Oncol.
  
  Volume: 33(6) Issue: 6 Pages: 57-57
- DOI
  10.1007/s12032-016-0773-5
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26460188, KAKENHI-PROJECT-26461152
[Journal Article] 多発性骨髄腫に対する新規薬剤療法のTDM （therapeutic drug monitoring：治療薬物モニタリング）2016
- Author(s)
  小林　敬宏、三浦　昌明、髙橋　直人
- Journal Title
  
  日本臨牀
  
  Volume: 1102号 Pages: 573-577
- Data Source
  KAKENHI-PROJECT-26461414
[Journal Article] Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.2015
- Author(s)
  Togashi M, Niioka T, Komatsuda A, Nara M, Okuyama S, Omokawa A, Abumiya M, Wakui H, Takahashi N, Miura M.
- Journal Title
  
  Eur J Clin Pharmacol.
  
  Volume: 71 Issue: 9 Pages: 1091-7
- DOI
  10.1007/s00228-015-1901-4
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460189
[Journal Article] Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.2015
- Author(s)
  Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Habuchi T, Satoh S, Miura M.
- Journal Title
  
  Int J Mol Sci.
  
  Volume: 16 Issue: 1 Pages: 1840-1854
- DOI
  10.3390/ijms16011840
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-26460189
[Journal Article] Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation2015
- Author(s)
  Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Habuchi T, Satoh S, Miura M.
- Journal Title
  
  Int J Mol Sci
  
  Volume: 16 Pages: 1840-1854
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K10636
[Journal Article] Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer2015
- Author(s)
  Kobayashi H, Sato K, Niioka T, Miura H, Ito H, Miura M
- Journal Title
  
  Clin Lung Cancer
  
  Volume: 4 Pages: 274-81
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] Effects of CYP3A5 polymorphism and the tacrolimus 12?h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis.2015
- Author(s)
  Niioka T, Komatsuda A, Kato S, Togashi M, Okuyama S, Omokawa A, Nara M, Wakui H, Takahashi N, Miura M.
- Journal Title
  
  Xenobiotica.
  
  Volume: 45 Pages: 1147-53
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460189
[Journal Article] 腎移植におけるミコフェノール酸の体内動態と個別化療法2015
- Author(s)
  三浦昌朋、佐藤　滋
- Journal Title
  
  Organ Biology
  
  Volume: 22 Pages: 49-56
- NAID
  130005098699
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K10636
[Journal Article] Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia2015
- Author(s)
  Miura M
- Journal Title
  
  Biological and Pharmaceutical Bulletin
  
  Volume: 38 Issue: 5 Pages: 645-654
- DOI
  10.1248/bpb.b15-00103
- NAID
  130005068088
- ISSN
  0918-6158, 1347-5215
- Language
  English
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] A Limited Sampling Model to Estimate Exposure to Lenalidomide in Multiple Myeloma Patients.2014
- Author(s)
  Shida S, Takahashi N, Miura M, Niioka T, Matsumoto M, Hagihara M, Kobayashi T, Abumiya M, Kameoka Y, Fujishima N, Tagawa H, Hirokawa M, Sawada K.
- Journal Title
  
  Ther Drug Monit.
  
  Volume: 印刷中
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Treatment of multiple myeloma in Akita: features and outcomes in the era of novel agents.2014
- Author(s)
  Shida S, Takahashi N, Niioka T, Kitabayashi A, Kawabata Y, Kume M, Saitoh H, Hatano Y, Ichikawa Y, Kuroki J, Motegi M, Kobayashi T, Kameoka Y, Tagawa H, Fujishima N, Yoshioka T, Hirokawa M, Miura M, Sawada K.
- Journal Title
  
  J Clin Exp Hematop
  
  Volume: 54 Pages: 89-93
- NAID
  130004886480
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.2014
- Author(s)
  Shida S, Takahashi N, Miura M, Niioka T, Matsumoto M, Hagihara M, Kobayashi T, Abumiya M, Kameoka Y, Fujishima N, Tagawa H, Hirokawa M, Sawada K.
- Journal Title
  
  Ther Drug Monit
  
  Volume: 36 Issue: 4 Pages: 505-9
- DOI
  10.1097/ftd.0000000000000034
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-26460188
[Journal Article] A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib2014
- Author(s)
  Miura M, Sato K, Miura H, Niioka T, Kobayashi H, Narita C, Ito H
- Journal Title
  
  Ther Drug Monit
  
  Volume: 36(1) Pages: 24-9
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.2014
- Author(s)
  Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K.
- Journal Title
  
  Biomark Res.
  
  Volume: 20;2(1) Issue: 1 Pages: 2-6
- DOI
  10.1186/2050-7771-2-6
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23590168, KAKENHI-PROJECT-25461431
[Journal Article] Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients.2014
- Author(s)
  Miura M, Takahashi N.
- Journal Title
  
  Rinsho Ketsueki
  
  Volume: 54 Pages: 1720-1729
- NAID
  10031196316
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.2014
- Author(s)
  Miura M, Sato K, Miura H, Niioka T, Kobayashi H, Narita C, Ito H.
- Journal Title
  
  Ther Drug Monit.
  
  Volume: 36(1) Pages: 24-9
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] 腎移植患者における免疫抑制剤の個別化療法2013
- Author(s)
  三浦昌朋, 佐藤滋
- Journal Title
  
  日病薬誌
  
  Volume: 49 Pages: 1061-1065
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Pharmaceutcal and genetic determinants for inter individual differences of tacrolimus bioavailability in renal transplant recipients.2013
- Author(s)
  Niioka T, Kaagaya H, Miura M, Numakura K, Saito M, Inoue T, Habuchi T, Satoh S.
- Journal Title
  
  Eur J Clin Pharmcol
  
  Volume: 69 Pages: 1659-1665
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.2013
- Author(s)
  Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K.
- Journal Title
  
  Haematologica.
  
  Volume: 98(9) Issue: 9 Pages: 1407-13
- DOI
  10.3324/haematol.2013.085167
- NAID
  120006986100
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients2013
- Author(s)
  Niioka T, Kagaya H, Miura M, Numakura K, Saito M, Inoue T, Habuchi T, Satoh S
- Journal Title
  
  Eur J Clin Pharmacol
  
  Volume: 69 Pages: 1659-1665
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients2013
- Author(s)
  Miura M, Takahashi N
- Journal Title
  
  Rinsho Ketsueki
  
  Volume: Vol.54 Pages: 1720-1729
- NAID
  10031196316
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Pharmacogenetics and circadian exposure of tacrolimus and its impact on the renal transplant outcome: a way to a personalized medicine for tacrolimus.2013
- Author(s)
  Satoh S, Saito M, Numakura K, Miura Y, Obara T, Tsuruta H, Narita S, Horikawa Y, Tsuchiya N, Habuchi T, Mitobe Y, Komatsuda A, Kagaya H, Miura M
- Journal Title
  
  Hirosaki Med J
  
  Volume: 64
- NAID
  110009614342
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] A limited sampling strategy to estimate the area under the concentration-time curve of tacrolimus modified-release once-daily preparation in renal transplant recipients2013
- Author(s)
  Niioka T, Miura M, Kagaya H, Saito M, Numakura K, Habuchi T, Satoh S
- Journal Title
  
  Ther Drug Monit
  
  Volume: 35 Pages: 228-232
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.2013
- Author(s)
  Hinai Y, Motoyama S, Niioka T, Miura M.
- Journal Title
  
  J Clin Pharm Ther.
  
  Volume: 38(6) Issue: 6 Pages: 498-503
- DOI
  10.1111/jcpt.12097
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] A limited sampling strategy to estimate under the concentration-time curve of tacrolimus modified-release once-daily preparation in renal transplant recipients.2013
- Author(s)
  Niioka T, Miura M, Kagaya H, Saito M, Numakura K, Habuchi T, Satoh S.
- Journal Title
  
  Ther Drug Monit
  
  Volume: 81 Pages: 308-312
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] グラセプタのトラフ値はプログラフと同等か?2013
- Author(s)
  佐藤滋, 新岡丈典, 加賀谷英彰, 沼倉一幸, 井上高光, 斎藤満, 小峰直樹, 秋濱晋, 成田伸太郎, 土谷順彦, 羽渕友則, 三浦昌朋
- Journal Title
  
  日本臨床腎移植学会雑誌
  
  Volume: 1 Pages: 78-81
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation2012
- Author(s)
  Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M
- Journal Title
  
  Transplantation
  
  Volume: 94 Pages: 1013-101
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia2012
- Author(s)
  Matsuoka A, Takahashi N, Miura M, Niioka T, Kawakami K, Matsunaga T, Sawada K
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 70(2) Issue: 2 Pages: 351-2
- DOI
  10.1007/s00280-012-1900-4
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] omparison pf pharmacokinetics and pjarmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.2012
- Author(s)
  Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.
- Journal Title
  
  Transplantation
  
  Volume: 94 Pages: 1013-1019
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure.2012
- Author(s)
  Onaka T, Takahashi N, Miura M, Yonezawa A, Imada K, Sawada K
- Journal Title
  
  Am J Hematol.
  
  Volume: 87 Issue: 4 Pages: 451-451
- DOI
  10.1002/ajh.23125
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival.2012
- Author(s)
  Numakura K, Satoh S, Tcuchiya N, Saito M, Maita S, Obara T, Tsuruta H, Inoue T, Narita S, Horikawa Y, Kagaya H, Miura M, Habuchi T.
- Journal Title
  
  Transplantation
  
  Volume: 94 Pages: 145-151
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation2012
- Author(s)
  Takahashi N, Miura M, Scott SA, Niioka T, Sawada K
- Journal Title
  
  J Hematol Oncol
  
  Volume: 5 Issue: 1 Pages: 23-23
- DOI
  10.1186/1756-8722-5-23
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients2012
- Author(s)
  Takahashi N, Miura M, Niioka T, Sawada K
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 69(4) Issue: 4 Pages: 999-1004
- DOI
  10.1007/s00280-011-1797-3
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Bile acid is important for gastrointestinal absorption of nilotinib.2012
- Author(s)
  Fujimi A, Takahashi N, Miura M, Kanisawa Y, Ono K, Sawada K.
- Journal Title
  
  Eur J Clin Pharmacol.
  
  Volume: 68 Issue: 11 Pages: 1575-6
- DOI
  10.1007/s00228-012-1282-x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Drug interaction between lenalidomide and itraconazole2012
- Author(s)
  Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K
- Journal Title
  
  Am J Hematol
  
  Volume: 87 Issue: 3 Pages: 338-9
- DOI
  10.1002/ajh.22260
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.2012
- Author(s)
  Takahashi N, Miura M, Niioka T, Sawada K.
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 69(4) Pages: 999-1004
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients2012
- Author(s)
  Kagaya H, Miura M, Niioka T, Saito M, Numakura K, Habuchi T, Satoh S
- Journal Title
  
  Antimicrob Agents Chemother
  
  Volume: 56 Pages: 825-829
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients2011
- Author(s)
  Miura M, Satoh S, Kagaya H, Saito M, et al
- Journal Title
  
  Pharmacogenomics
  
  Volume: 12 Pages: 977-984
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] 薬物動態、薬力学および薬理遺伝学に基づくミコフェノール酸の個別化療法の確立2011
- Author(s)
  三浦昌朋, 佐藤滋
- Journal Title
  
  臨床薬理の進歩
  
  Volume: 別冊 Pages: 90-98
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Factors Increasing Quantitative Interstitial Fibrosis from 0-hour to 1-year in Living Kidney Transplant Patients Receiving Tacrolimus.2011
- Author(s)
  Miura Y, Satoh S, Saito M, Numakura K, Inoue T, Obara T, Tsuruta H, Narita S, Horikawa Y, Tsuchiya N, Komatsuda A, Kagaya H, Miura M, Habuchi T.
- Journal Title
  
  Transplantation 91
  
  Pages: 78-85
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.2011
- Author(s)
  Takahashi N, Miura M.
- Journal Title
  
  Pharmacology.
  
  Volume: 87(5-6) Pages: 241-8
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase2011
- Author(s)
  Takahashi N, Miura M
- Journal Title
  
  Pharmacology
  
  Volume: 87(5-6) Issue: 5-6 Pages: 241-8
- DOI
  10.1159/000324900
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Monitoring of mycophenolic acid predose concentration in the maintenance phase more than one year after renal transplantation2011
- Author(s)
  Miura M, Niioka T, Kato S, Kagaya H, Saito M, Habuchi T, Satoh S
- Journal Title
  
  Ther Drug Monit
  
  Volume: 33 Pages: 295-302
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year In living kidney transplant patients receiving tacrolimus.2011
- Author(s)
  Miura Y, Satoh S, Saito M, Miura M, et al.
- Journal Title
  
  Transplantation
  
  Volume: 91 Pages: 78-85
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection2011
- Author(s)
  Miura M, Takahashi N, Sawada K
- Journal Title
  
  J Chromatogr Sci
  
  Volume: 49(5) Pages: 412-5
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation2011
- Author(s)
  Miura M, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, Satoh S
- Journal Title
  
  J Clin Pharm Ther
  
  Volume: 36 Pages: 208-216
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.2011
- Author(s)
  Miura M, Takahashi N, Sawada K.
- Journal Title
  
  J Chromatogr Sci.
  
  Volume: 49(5) Pages: 412-5
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23590168
[Journal Article] Pharmacogenetic determinants for interindividual difference of tacrolimus2011
- Author(s)
  Miura M, Niioka T, Kagaya H, Saito M, Hayakari M, Habuchi T, Satoh S.
- Journal Title
  
  J Clin Pharm Ther
  
  Volume: 36 Pages: 208-216
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus2011
- Author(s)
  Miura Y, Satoh S, Saito M, Numakura K, Inoue T, Obara T, Tsuruta H, Narita S, Horikawa Y, Tsuchiya N, Komatsuda A, Kagaya H, Miura M, Habuchi T
- Journal Title
  
  Transplantation
  
  Volume: 91 Pages: 78-85
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592378
[Journal Article] Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation2010
- Author(s)
  Kagaya H, Miura M, Saito M, Habuchi T, Satoh S.
- Journal Title
  
  Basic Clin Pharmacol Toxicol
  
  Volume: 107 Pages: 631-636
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.2009
- Author(s)
  Satoh S, Saito M, Inoue T, Kagaya H, Miura M, Inoue K, Komatsuda A, Tsuchiya N, Suzuki T, Habuchi T.
- Journal Title
  
  Eur J Clin Pharmacol 65
  
  Pages: 473-481
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Telmisartan pharmacokinetics in Japanese renal transplant recipients2009
- Author(s)
  Miura M, Satoh S, Inoue K, et.al.
- Journal Title
  
  Clin Chim Acta 399
  
  Pages: 83-87
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation.2009
- Author(s)
  Miura M, Satoh S, Kagaya H, Saito M, Inoue T, Tsuchiya N, Suzuki T, Habuchi T.
- Journal Title
  
  Eur J Clin Pharmacol 65
  
  Pages: 1047-1053
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant recipients.2009
- Author(s)
  Miura M, Satoh S, Niioka T, et al.
- Journal Title
  
  Ther Drug Monit 31
  
  Pages: 467-474
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients2009
- Author(s)
  Miura M, Kagaya H, Satoh S, et.al.
- Journal Title
  
  Ther Drug Monit (In press)
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation.2009
- Author(s)
  Miura M, Satoh S, Kagaya H, et al.
- Journal Title
  
  Eur J Clin Pharmcol 65
  
  Pages: 1047-1053
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Influence of CYP3A5, ABCB1 and NR112 polymorphisms onprednisolone pharmacokinetics in renal transplant recipients2008
- Author(s)
  Miura M, Satoh S, Inoue K, et.al.
- Journal Title
  
  Steroids 73
  
  Pages: 1052-1059
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation2008
- Author(s)
  Miura M, Satoh S, Inoue K, et.al.
- Journal Title
  
  Ther Drug Monit 30
  
  Pages: 46-51
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients2008
- Author(s)
  Kagaya H, Miura M, Satoh S, et.al.
- Journal Title
  
  J Clin Pharm Ther 33
  
  Pages: 193-201
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Limited sampling strategy for simultaneous estimation of theare under the concentration-time curve of tacrolimus and myconhenolic acid in adult renal transnlant recinients2008
- Author(s)
  Miura M, Satoh S, Niioka T, et.al.
- Journal Title
  
  Ther Drug Monit 30
  
  Pages: 52-59
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Journal Article] Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients.2008
- Author(s)
  Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, Tsuchiya N, Suzuki T, Habuchi T.
- Journal Title
  
  Brit J Clin Pharmacol 66
  
  Pages: 207-214
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20591894
[Patent] 高速液体クロマトグラフィ法を用いた抗がん剤の血中濃度定量方法2014
- Inventor(s)
  三浦昌朋
- Industrial Property Rights Holder
  三浦昌朋
- Industrial Property Rights Type
  特許
- Filing Date
  2014-11-27
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 分子標的治療薬のHPLC法を用いた定量とTDMの臨床実装2022
- Author(s)
  三浦昌朋
- Organizer
  第38回日本TDM学会・学術大会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] 非小細胞肺がんにおけるアファチニブ血中濃度と副作用と関係2022
- Author(s)
  横田隼人，佐藤一洋，坂本　祥，奥田佑道，浅野真理子，竹田正秀，中山勝敏，三浦昌朋
- Organizer
  第32回日本医療薬学会年会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] 血漿濃度を用いたオシメルチニブ治療の多施設前向き観察研究2022
- Author(s)
  井草龍太郎，福原達朗，今井一博，中川　拓，横田隼人，渡邉香奈，鈴木　綾，盛田麻美，井上　彰，三浦昌朋，南谷佳弘，前門戸任
- Organizer
  第62回日本呼吸器学会学術講演会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial2021
- Author(s)
  Kumagai T, Murai K, Ureshino H, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Mita M, Uoshima N, Kiguchi T, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, et al.
- Organizer
  63rd ASH Annual Meeting and Exposition
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] 進行大腸がん患者におけるレゴラフェニブの血中濃度と治療効果の関連2021
- Author(s)
  野田哲史，土手賢史，石塚保亘，寺澤哲志，後藤愛実，高橋克之，佐野村誠，谷　眞至，安藤　朗，三浦昌朋，後藤昌弘，寺田智祐
- Organizer
  医療薬学フォーラム2021/第29回クリニカルファーマシーシンポジウム
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] オシメルチニブ治療における血漿濃度測定の有用性を検討する前向き観察研究2021
- Author(s)
  今井一博，福原達朗，中川　拓，井草龍太郎，横田隼人，渡邉香奈，鈴木　綾，盛田麻美，井上　彰，三浦昌朋，南谷佳弘，前門戸任
- Organizer
  第62回日本肺癌学会学術集会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] Effect of SLC22A2 SNP and bosutinib concentrations on serum creatinine in patients taking bosutinib2021
- Author(s)
  Abumiya M, Takahashi N, Takahashi S, Yoshioka T, Kameoka, Y, Miura M
- Organizer
  第83回日本血液学会学術集会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] Gefitinibの血中濃度と薬物動態に関する遺伝子多型との関係性についての検討2021
- Author(s)
  坂本　祥, 佐藤一洋, 横田隼人, 赤嶺由美子, 奥田佑道, 浅野真理子, 竹田正秀, 三浦昌朋, 中山勝敏
- Organizer
  第61回日本呼吸器学会学術講演会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] A prospective observational study of osimertinib using plasma concentrations in NSCLC with acquired EGFR T790M mutation2021
- Author(s)
  Nakagawa T, Fukuhara T, Imai K, Igusa R, Yokota H, Watanabe K, Suzuki A, Morita M, Inoue A, Miura M, Minamiya Y, Maemondo M
- Organizer
  2021 World Conference on Lung Cancer
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] 薬物投与設計時に必要な医療技術の充実化を目指して2020
- Author(s)
  三浦昌朋
- Organizer
  第30回医療薬学会年会
- Data Source
  KAKENHI-PROJECT-20K07150
[Presentation] より効果的な抗がん剤の使用を考える～TDMと時間薬理の活用～分子標的抗がん剤のCCDによる早期寛解2019
- Author(s)
  三浦昌朋
- Organizer
  第27回クリニカルファーマシーシンポジウム
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 慢性骨髄性白血病治療薬チロシンキナーゼ阻害剤の血中濃度を用いた治療マネジメントupdate2019
- Author(s)
  三浦昌朋
- Organizer
  第81回日本血液学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 分子標的抗がん剤による治療に血中濃度をどう活かすか?～TDMの真価を問う～特定の血中濃度をターゲットにした分子標的抗がん剤治療の実践2019
- Author(s)
  三浦昌朋
- Organizer
  第36回日本TDM学会・学術大会
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] Effects of polymorphisms of NR1I2, CYP3A4 and ABC transporters on the concentrations of bosutinib2018
- Author(s)
  Abumiya, M., Mita, A., Yoshioka, T., Kameoka, Y., Takahashi, N., Miura, M.
- Organizer
  第80回日本血液学会学術集会
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 分子標的抗がん剤のTDM診療報酬拡大を目指して　診療報酬対象薬剤の拡大に向けての経緯と測定方法2018
- Author(s)
  三浦昌朋
- Organizer
  第35回日本TDM学会・学術大会
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia2018
- Author(s)
  Mita, A., Abumiya, M., Takahashi, S., Kameoka, Y., Miura, M., Takahashi, N
- Organizer
  60th American Society of Hematology Annual Meeting and Exposition
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] fficacy and Safety of Tyrosine Kinase Inhibitors for Treatment of Newly Diagnosed Chronic Myeloid Leukemia: Results Using Data Obtained with the New Target System from the Japanese Registry.2018
- Author(s)
  Takahashi, N., Kizaki, M., Miura, M., Kawaguchi, T., Suzuki, R., Yamamoto, K., Ohnishi, K., Matsumura, I., Naoe, T., Akashi, K.
- Organizer
  60th American Society of Hematology Annual Meeting and Exposition
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] ポナチニブのターゲット血中濃度に基づいた処方提案2017
- Author(s)
  鐙屋舞子，高橋直人，三浦昌朋
- Organizer
  日本医療薬学会第27回年会
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] クロマトグラフィーを用いた分子標的抗がん剤治療戦略2017
- Author(s)
  三浦昌朋
- Organizer
  第24回クロマトグラフィーシンポジウム
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 病院薬剤部は基礎と臨床の融合に貢献できているのか?　－研究室としての機能を考える－．病棟薬剤師による基礎研究に基づいた抗がん剤治療提案2017
- Author(s)
  三浦昌朋
- Organizer
  医療薬学フォーラム2017/第25回クリニカルファーマシーシンポジウム
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 臨床化学の進歩が変える薬物治療．血中濃度を用いた分子標的抗がん剤の治療戦略普及への挑戦2017
- Author(s)
  三浦昌朋
- Organizer
  日本薬学会第137年会
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 腎移植患者におけるタクロリムス体内曝露量の個体間変動に及ぼすCYP3A5遺伝子多型およびエベロリムスの影響2017
- Author(s)
  加賀谷　英彰、新岡　丈典、齋藤　満、井上　高光、沼倉　一幸、羽渕　友則、佐藤　滋、三浦　昌朋
- Organizer
  医療薬学会
- Data Source
  KAKENHI-PROJECT-26460189
[Presentation] 分子標的治療薬の臨床薬理学的研究．慢性骨髄性白血病患者に対するTKIのPK/PD研究2017
- Author(s)
  三浦昌朋
- Organizer
  第15回日本臨床腫瘍学会学術集会
- Data Source
  KAKENHI-PROJECT-17K08408
[Presentation] 血中濃度を用いた分子標的抗がん剤の治療戦略普及への挑戦2017
- Author(s)
  三浦昌朋
- Organizer
  日本薬学会第136年会
- Place of Presentation
  仙台
- Year and Date
  2017-03-25
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 移植非適応未治療多発性骨髄腫患者に対するLd療法およびレナリドミドの至適血漿中濃度の検討2017
- Author(s)
  小林敬宏, 三浦昌朋, 新岡丈典, 鐙屋舞子, 大八木秀明, 篠原良徳, 茂木睦仁, 黒木淳, 西成民夫, 川端良成, 北林淳, 道下吉広, 池田翔, 志田青慈, 吉岡智子, 高橋直人
- Organizer
  日本骨髄腫学会
- Place of Presentation
  東京
- Year and Date
  2017-05-27
- Data Source
  KAKENHI-PROJECT-26461414
[Presentation] 遺伝子多型情報を用いた抗がん剤と免疫抑制剤の個別化投与設計2016
- Author(s)
  新岡丈典，三浦昌朋
- Organizer
  日本薬物動態学会第31回年会
- Place of Presentation
  松本
- Year and Date
  2016-10-13
- Invited
- Data Source
  KAKENHI-PROJECT-26460189
[Presentation] Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients.2016
- Author(s)
  Norihiko Tsuchiya, Ryoma Igarashi, Naoko Suzuki-Honma, Nobuhiro Fujiyama, Shintaro Narita, Takamitsu Inoue, Mitsuru Saito, Susumu Akihama, Hiroshi Tsuruta, Masatomo Miura, Tomonori Habuchi
- Organizer
  2016 American Society of Clinical Oncology (ASCO) Annual Meeting
- Place of Presentation
  Chicago
- Year and Date
  2016-06-03
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Regorafenibおよび主代謝物M2，M5の同時定量法の開発と臨床応用2016
- Author(s)
  藤田一馬，柴田浩行，三浦昌朋
- Organizer
  日本医療薬学会第26回年会
- Place of Presentation
  京都
- Year and Date
  2016-09-17
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] The impact of UGT1A1 and SLCO1B1 genetic polymorphisms and pharmacokinetics of axitinib on clinical safety and efficacy in patients with metastatic renal cell carcinoma.2016
- Author(s)
  Shintaro Narita, Ryoma Igarashi, Norihiko Tsuchiya, Takamitsu Inoue, Nobuhiro Fujiyama, Kazuyuki Numakura, Hiroshi Tsuruta, Hideaki Kagaya, Mitsuru Saito, Takenori Niioka, Masatomo Miura, Shigeru Satoh, Tomonori Habuchi
- Organizer
  2016 American Society of Clinical Oncology (ASCO) Annual Meeting
- Place of Presentation
  Chicago
- Year and Date
  2016-06-03
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Lenalidomide/dexamethasone salvage therapy for MM with stepwise evaluation for practical dose2016
- Author(s)
  Reiko Watanabe, Hideo Yagi, Jian Hua, Masatomo Miura, Masao Hagihara, Naoto Takahashi, Michihide Tohuhira, Masatiro Kizaki
- Organizer
  第78回日本血液学会学術集会
- Place of Presentation
  横浜
- Year and Date
  2016-10-13
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] フィラデルフィア染色体陽性慢性骨髄性白血病患者におけるボスチニブの初期と維持期の血中濃度と効果の関係2016
- Author(s)
  鐙屋舞子，新岡丈典，高橋直人，三浦昌朋
- Organizer
  日本医療薬学会第26回年会
- Place of Presentation
  京都
- Year and Date
  2016-09-17
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 分子標的抗がん剤の血中濃度測定方法の開発と臨床応用2016
- Author(s)
  三浦昌朋
- Organizer
  日本薬学会第136年会
- Place of Presentation
  横浜
- Year and Date
  2016-03-27
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Two-year consolidation by Nilotinib might improve the TFR of STIM trial in CML with DMR2016
- Author(s)
  Kaichi Nishiwaki, Naoto Takahashi, Chiaki Nakaseko, Hisashi Wakita, Koji Sano, Chikako Ohwada, Nobuyuki Aotsuka, Jun Kuroki, Hideo Kimura, Hideyoshi Noji, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Masatomo Miura, Kenichi Sawada
- Organizer
  第78回日本血液学会学術集会
- Place of Presentation
  横浜
- Year and Date
  2016-10-13
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 臨床濃度範囲でエベロリムスはタクロリムス体内動態に影響しない2015
- Author(s)
  新岡丈典, 加賀谷英彰, 齋藤満, 井上高光, 沼倉一幸, 羽渕友則, 佐藤滋, 三浦昌朋
- Organizer
  第51回日本移植学会総会
- Place of Presentation
  熊本
- Year and Date
  2015-10-01
- Data Source
  KAKENHI-PROJECT-26460189
[Presentation] 分子標的抗がん剤の個別化治療法の確立2015
- Author(s)
  三浦昌朋
- Organizer
  日本薬学会第135年会
- Place of Presentation
  神戸
- Year and Date
  2015-03-26
- Invited
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Application of individual therapeutic drug monitoring of imatinib against GIST treatment2015
- Author(s)
  Hiroyuki Shibata, Masahiro Inoue, Masatomo Miura
- Organizer
  第13回日本臨床腫瘍学会学術集会
- Place of Presentation
  札幌
- Year and Date
  2015-07-16
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 進行性腎細胞癌患者におけるアキシチニブの治療効果はトラフ濃度と関連する2015
- Author(s)
  藤山信弘、五十嵐龍馬、土谷順彦、佐々木克也、本間直子、成田伸太郎、井上高光、齋藤満、秋濱　晋、鶴田　大、奥山　慎、新岡丈典、三浦昌朋、羽渕友則、佐藤滋
- Organizer
  日本薬学会第135年会
- Place of Presentation
  神戸
- Year and Date
  2015-03-27
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 分子標的治療薬のTDMによる個別化2015
- Author(s)
  三浦昌朋
- Organizer
  6.医療薬学フォーラム2015/第23回クリニカルファーマシーシンポジウム
- Place of Presentation
  名古屋
- Year and Date
  2015-07-04
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Pharmacokinetics of bosutinib and its induced-diarrhea in Ph-positive chronic myeloid leukemia2015
- Author(s)
  Maiko Abumiya, Naoto Takahashi, Takenori Niioka, Saori Takahashi, Akiko Mita, Takahiro Kobayashi, Yoshihiro Kameoka, Tomoko Yoshioka, Naohito Fujishima, Hiroyuki Tagawa, Kenichi Sawada, Masatomo Miura
- Organizer
  第77回日本血液学会学術集会
- Place of Presentation
  金沢
- Year and Date
  2015-10-16
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Therapeutic Drug Monitoring of Imatinib2015
- Author(s)
  Masatomo Miura
- Organizer
  第13回日本臨床腫瘍学会学術集会
- Place of Presentation
  札幌
- Year and Date
  2015-07-16
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] ループス腎炎患者の急性腎障害発症に及ぼすタクロリムスの血中濃度とCYP3A5遺伝子多型の影響2015
- Author(s)
  富樫賢, 新岡丈典, 奈良瑞穂, 面川歩, 奥山慎, 加藤正太郎, 涌井秀樹, 三浦昌朋, 小松田敦
- Organizer
  第58回日本腎臓学会学術総会
- Place of Presentation
  名古屋
- Year and Date
  2015-06-05
- Data Source
  KAKENHI-PROJECT-26460189
[Presentation] ゲフィチニブのPK/PD に及ぼす体内動態関連遺伝子多型の影響2015
- Author(s)
  小林裕幸、佐藤一洋、新岡丈典、三浦肇、伊藤宏、三浦昌朋
- Organizer
  日本薬学会第135年会
- Place of Presentation
  神戸
- Year and Date
  2015-03-28
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 経口分子標的抗がん剤の血中濃度を用いた治療戦略2015
- Author(s)
  三浦昌朋
- Organizer
  日本臨床薬理学会第36回学術総会
- Place of Presentation
  東京
- Year and Date
  2015-12-09
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Correlation of dasatinib pharmacokinetics with clinical response and adverseevents2015
- Author(s)
  Akiko Mita, Masatomo Miura, Takenori Niioka, Maiko Abumiya Takahiro Kobayashi, Saori Takahashi, Yoshihiro Kameoka, Tomoko Yoshioka, Naoto Takahashi
- Organizer
  第77回日本血液学会学術集会
- Place of Presentation
  金沢
- Year and Date
  2015-10-16
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 膠原病患者におけるタクロリムスとイトラコナゾールとの薬物相互作用に及ぼすCYP3A5およびABCB1遺伝子多型の影響2015
- Author(s)
  新岡丈典, 富樫賢, 小松田敦, 奈良瑞穂, 奥山慎, 面川歩, 鐙屋舞子, 涌井秀樹, 高橋直人, 三浦昌朋
- Organizer
  日本医療薬学会第25回年会
- Place of Presentation
  横浜
- Year and Date
  2015-11-21
- Data Source
  KAKENHI-PROJECT-26460189
[Presentation] Influence of CYP3A5 gene polymorphisms on pharmacokinetics of tacrolimus modified-release once-daily after hematopoietic stem cell transplantation.2015
- Author(s)
  Takaya Yamashita, Naohito Fujishima, Masatomo Miura, Takenori Niioka, Maiko Abumiya, Kazuaki Teshima, Kumi Ubukawa, Miho Nara, Masumi Fujishima, Yoshihiro Kameoka, Makoto Hirokawa, Naoto Takahashi
- Organizer
  20th Congress of European Hematology Association
- Place of Presentation
  Vienna
- Year and Date
  2015-06-11
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26460189
[Presentation] Pharmacokinetcis of lenalidomide in patients with multiple myeloma on hemodialysis.2014
- Author(s)
  Takahiro Kobayashi, Naoto Takahashi, Masatomo Miura, Ayano Ohara, Yoshihiro Mitishita, Tekenori Niioka, Maiko Abumiya, Seiji Shida, Kumi Ubukawa, Naohito Fujishima, Yoshihiro Kameoka, Hiroyuki Tagawa, Kenichi Sawada
- Organizer
  第76回日本血液学会学術集会
- Place of Presentation
  大阪
- Year and Date
  2014-10-31
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 経口分子標的抗がん剤のTDMによる個別化治療と測定方法2014
- Author(s)
  三浦昌朋
- Organizer
  日本臨床薬理学会第35回学術総会
- Place of Presentation
  愛媛
- Year and Date
  2014-12-05
- Invited
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Clarithromycin Elevates the Plasma Concentration of Lenalidomide Via Inhibition of MDR1.2014
- Author(s)
  Naoki Takezako, Masatomo Miura, Akihisa Nagata, Naohiro Sekiguchi, Takenori Niioka, Seiji Shida, Takahiro Kobayashi, Maiko Abumiya, Akiyoshi Miwa, Naoto Takahashi
- Organizer
  56th American Society of Hematology Annual Meeting and Exposition
- Place of Presentation
  サンフランシスコ
- Year and Date
  2014-12-06
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] レナリドマイドのTDMの有用性～TM-Rev 試験からの報告2014～2014
- Author(s)
  新岡丈典、高橋直人、志田青慈、小林敬宏、鐙屋舞子、澤田賢一、三浦昌朋
- Organizer
  医療薬学フォーラム2014/第22回クリニカルファーマシーシンポジウム
- Place of Presentation
  東京
- Year and Date
  2014-06-28
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 非小細胞肺癌患者のゲフィチニブによる治療に複数規格は必要ないか？2014
- Author(s)
  新岡丈典, 佐藤一洋, 小林裕幸，三浦　肇，伊藤　宏，三浦昌朋
- Organizer
  日本薬学会第134年会
- Place of Presentation
  熊本
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Blood concentration of lenalidomide would change with the existence of clarithromycin.2014
- Author(s)
  Naoki Takezako, Naohiro Sekiguchi, Akihisa Nagata, Masatomo Miura, Tekenori Niioka, Seiji Shida, Takahiro Kobayashi, Maiko Abumiya, Naoto Takahashi
- Organizer
  第76回日本血液学会学術集会
- Place of Presentation
  大阪
- Year and Date
  2014-10-31
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] 血液がん領域におけるTDM～イマチニブと第2世代TKI～2014
- Author(s)
  三浦昌朋
- Organizer
  第31回日本TDM学会・学術大会
- Place of Presentation
  東京
- Year and Date
  2014-06-01
- Invited
- Data Source
  KAKENHI-PROJECT-26460188
[Presentation] Lack of clinical factors increasing quantitative interstitial fibrosis after renal transplantation under a lower target trough strategy of tacrolimus2013
- Author(s)
  Komine, N., Satoh, S., Numakura, K., Saito, M., Inoue, T., Narita, S., Miura, Y., Tsuchiya, N., Kagaya, H., Miura, M., Habuchi, H.
- Organizer
  The 108th Annunal Meeting of the American Urological Association
- Place of Presentation
  San Diego,USA
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] CYP3A5遺伝子多型に基づくグラセプタ個別投与による移植後早期の薬物動態と腎機能への影響.2013
- Author(s)
  佐藤　滋、沼倉一幸、齊藤　満、井上高光、秋濱　晋、成田伸太郎、土谷順彦、羽渕友則、加賀谷英彰、新岡丈典、三浦昌朋
- Organizer
  第56回日本腎臓学会学術総会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] 慢性骨髄性白血病に対するBCR-ABLチロシンキナーゼ阻害剤の血中濃度を用いた治療マネジメント2013
- Author(s)
  三浦昌朋
- Organizer
  第75回日本血液学会学術集会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Pharmaceutical and genetic determinants for inter-individual differences of tacrolimus bioavailability in renal transplant recipients.2013
- Author(s)
  Niioka T, Miura M, Kagaya H, Numakura K, Saito M, Inoue T, Habuchi T, Satoh S
- Organizer
  The 13rd Congress of the Asian Society of Transplantation
- Place of Presentation
  Kyoto
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] Inter- and intra-individual variability of nilotinib plasma trough concentration in CML patients.2013
- Author(s)
  2) Maiko Abumiya, Masatomo Miura, Naoto Takahashi, Takenori Niioka, Kenichi Sawada
- Organizer
  第75回日本血液学会学術集会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Pharmacokinetics and CYP3A5 pharmacogentics for once- versus twice-daily tacrolimus from first dosing day to 1 year post-transplantation.2013
- Author(s)
  Satoh S, Niioka T, Kagaya H, Numakura K, Saito M, Inoue T, Komine N, Akihama S, Narita S, Tsuchiya T, Habuchi T, Miura M.
- Organizer
  The 13rd Annual Meeting of the American Transplant Congress
- Place of Presentation
  Seattle
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] Lack of clinical factors increasing quantitative interstitial fibrosis after renal transplantation under a lower target trough strategy of tacrolimus2013
- Author(s)
  Komine N, Satoh S, Numakura K, Saito M, Inoue T, Narita S, Miura Y, Tsuchiya N, Kagaya H, Miura M, Habuchi T.
- Organizer
  The 13rd Annual Meeting of the American Transplant Congress
- Place of Presentation
  Seattle
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] Inter- and intra-individual variability of nilotinib plasma trough concentration in CML patients2013
- Author(s)
  Abumiya M, Miura M, Takahashi N, Niioka T, Sawada K
- Organizer
  第75回日本血液学会学術集会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Pharmacokinetics and CYP3A5 pharmacogenetics for once- versus twice-daily tacrolimus from first dosing day to 1 year post-transplantation2013
- Author(s)
  Satoh, S., Niioka, T., Kagaya, H., Numakura, K., Saito, M., Inoue, T., Komine, N., Akihama, S., Narita, S., Tsuchiya, T., Habuchi, T., Miura, M.
- Organizer
  The 13rd Annunal Meeting of the American Transplant Congress
- Place of Presentation
  Seattl
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] 進行性腎細胞がん患者におけるスニチニブ血中濃度モニタリングによる副作用発現予測の検討2013
- Author(s)
  藤山信弘，土谷順彦，羽渕友則，三浦昌朋
- Organizer
  4. 医療薬学フォーラム2013／第21回クリニカルファーマシーシンポジウム
- Place of Presentation
  金沢
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] ダサチニブと胃酸分泌抑制剤との相互作用2012
- Author(s)
  三浦昌朋,高橋直人,新岡丈典,澤田賢一
- Organizer
  日本薬学会第132年会
- Place of Presentation
  札幌
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] チロシンキナーゼ阻害剤のTDM2012
- Author(s)
  三浦昌朋
- Organizer
  医療薬学フォーラム2012/第20回クリニカルファーマシーシンポジウム
- Place of Presentation
  福岡
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Multicenter Phase II Clinical Trial of Nilotinib for Patients with Imatinib-Resistant or Intolerant CML from the East Japan CML Study Group (EJCML) Trial : Evaluation of Molecular Responses by the BCR-ABL1 Mutational Status and Plasma Trough Concentration of Nilotinib2012
- Author(s)
  Takahashi N, Miura M, et al
- Organizer
  54th American Society of Hematology Annual Meeting and Exposition
- Place of Presentation
  Atlanta
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Posttransplant diabetes mellitus in adlt renal transplant recipients: incidence, clinical characteristics, tacrolimus pharamcokinetics, and related genomic polymorphim2012
- Author(s)
  Numakura K, Satoh S, Tsuchiya N, Saito M, Maita S, Obara T, Inoue T, Narita S, Horikawa Y, Kagaya H, Miura M, Habuchi T
- Organizer
  The 107th Annunal Meeting of the American Urological Association
- Place of Presentation
  Atlanta
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] Personalized initial dose of tacrolimus based on CYP3A5 polymorphism and its impact on 1-month graft function: a preliminary experience2012
- Author(s)
  Satoh S, Numnakura K, Maita S, Obara T, Inoue T, Narita S, Horikawa Y, Tsuchiya N, Habuchi T, Kagaya H, Miura M.
- Organizer
  24 th International Congress of the Transplantation Society
- Place of Presentation
  Berlin
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] Personalized initial dose of tacrolimus based on the CYP3A5 polymorphism and its impact on the 1-month graft function: a preliminary experience2012
- Author(s)
  Satoh S, Numakura K, Miura Y, Saito M, Maita S, Obara T, Inoue T, Narita S, Horikawa Y, Tsuchiya N, Habuchi T, Kagaya H, Miura M
- Organizer
  The 107th Annunal Meeting of the American Urological Association, May, Atlanta
- Place of Presentation
  Atlanta
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] 経口分子標的治療薬の個別化治療2012
- Author(s)
  三浦昌朋,高橋直人
- Organizer
  第33回日本臨床薬理学会学術総会
- Place of Presentation
  沖縄
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Multicenter phase II clinical trial of Nilotinib for patients with Imatinib-resistance or -intolerant CML from the East Japan CML Study Group (EJCML): Evaluation of molecular response by BCR-ABL1 mutation status and plasma trough concentration of Nilotinib2012
- Author(s)
  Takahashi N, Miura M, Niioka T, et al
- Organizer
  ASH Annual Meeting
- Place of Presentation
  アトランタ
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] 遺伝子多型情報とTDMに基づいたイマチニブ個別化療法2011
- Author(s)
  三浦　昌朋、高橋　直人
- Organizer
  第28回　日本TDM学会
- Place of Presentation
  広島
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] タクロリムス薬物動態に及ぼすCYP3A4*1G遺伝子多型の影響とCYP3A5*1/*3との比較2011
- Author(s)
  佐藤滋、三浦昌朋、加賀谷英彰、沼倉一幸、斎藤満、土谷順彦、羽渕友則
- Organizer
  第47回日本移植学会総会
- Place of Presentation
  仙台
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] 遺伝子多型情報とTDMに基づいたイマチニブ個別化療法2011
- Author(s)
  三浦昌朋
- Organizer
  第28回日本TDM学会・学術大会
- Place of Presentation
  広島
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Factors assoiciated with quantitative interstitial fibrosis at 0-hour (donor) biopsy by computerized image analysis in living donors.2011
- Author(s)
  Miura Y, Satoh S, Saito M, et al.
- Organizer
  The 106th Annual Meeting of the American Urological Association
- Place of Presentation
  Washington DC
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] Basiliximab induction therapy combined with a lower target trough level of tacrolimus and low dose of mycophenolate mofetil decreased interstitial fibrosis at 1-year posttransplantation and improved the 5-year graft survival2011
- Author(s)
  Satoh S, Numakura K, Saito M, Miura Y, Obara T, Tsuruta H, Inoue T, Narita S, Horikawa Y, Tsuchiya N, Habuchi T, Kagaya H, Miura M
- Organizer
  The 106th Annual Meeting of the American Urological Association
- Place of Presentation
  Washington DC
- Data Source
  KAKENHI-PROJECT-23592378
[Presentation] イマチニブ服用患者に対して我々薬剤師ができること2011
- Author(s)
  三浦　昌朋
- Organizer
  日本病院薬剤師会第一回東北ブロック学術大会
- Place of Presentation
  弘前
- Data Source
  KAKENHI-PROJECT-23590168
[Presentation] Clinical risk factors for increased interstitial fibrosis by computerized image analysis after renal transplantation.2010
- Author(s)
  Miura Y., Satoh S., Saito M., Numakura K., Narita S., Horikawa Y., Tsuchiya N., Habuchi T.
- Organizer
  The Annunal Meeting of the American Transplant Congress(Poster of Distinction.)
- Place of Presentation
  San Diego.
- Data Source
  KAKENHI-PROJECT-20591894
[Presentation] No impact of agen on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone one month after renal transplantation.2010
- Author(s)
  Satoh S., Saito M., Numakura K., Tsuruta H., Obara T., Inoue T., Narita S., Horikawa Y., Tsuchiya N., Habuchi T., Kagaya H., Miura M.
- Organizer
  The Annunal Meeting of the American Transplant Congress
- Place of Presentation
  San Diego.
- Data Source
  KAKENHI-PROJECT-20591894
[Presentation] Clinical risk factors for increased interstitial fibrosis by computerized image analysis after renal transplantation.2010
- Author(s)
  Miura Y., Satoh S., Saito M., Numakura K., Tsuruta H., Obara T., Inoue T., Narita S., Horikawa Y., Tsuchiya N., Habuchi T.
- Organizer
  The 104th Annunal Meeting of the American Urological Association(Best of Posters Award.)
- Place of Presentation
  San Francisco.
- Data Source
  KAKENHI-PROJECT-20591894
[Presentation] Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pahrmacogenetics in the early and maintenace stages in renal transplant recipients.2009
- Author(s)
  Satoh S., Saito M., Kagaya H., Miura M., Inoue K., Miura Y., Numakura K., Kumazawa T., Tsuchiya N., Habuchi T.
- Organizer
  The Annunal Meeting of the American Transplant Congress
- Place of Presentation
  Boston
- Data Source
  KAKENHI-PROJECT-20591894
[Presentation] Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus and mycophenolate mofetil.2008
- Author(s)
  Shigeru Satoh, Kazuyuki Numakura, Mitsuru Saito, Takamitus Inoue, Kazuyuki Inoue, Masatomo Miura, Hideaki Kagaya, Hiroshi Tsuruta, Takashi Obara, Teruaki Kumazawa, Takeshi Yuasa, Norihiko Tsuchiya, Toshio Suzuki, Tomonori Habuchi
- Organizer
  The Annunal Meeting of the American Transplant Congress
- Place of Presentation
  Tolonto, USA
- Data Source
  KAKENHI-PROJECT-20591894
[Presentation] Influence of CYP3A5 polymorphism on tacrolimus trough concentrations and acute rejection or chronic allogaft nephropathy in renal transplant recipients.2008
- Author(s)
  Shigeru Satoh, Mitsuru Saito, Takamitus Inoue, Hideaki Kagaya, Masatomo Miura, Kazuyuki Inoue, Tomonori Habuchi
- Organizer
  The Annunal Meeting of the American Transplant Congress
- Place of Presentation
  Tolonto, USA.
- Data Source
  KAKENHI-PROJECT-20591894
[Presentation] タクロリムス至適投与量に対する決定要因の経時的検討
- Author(s)
  新岡丈典、加賀谷英彰、齋藤満、井上高光、沼倉一幸、羽渕友則、佐藤滋、三浦昌朋
- Organizer
  第50回日本移植学会総会
- Place of Presentation
  京王プラザホテル(東京)
- Year and Date
  2014-09-10 – 2014-09-12
- Data Source
  KAKENHI-PROJECT-26460189

1. TAKAHASHI Naoto (80344753)

# of Collaborated Projects: 5 results

# of Collaborated Products: 44 results
2. SATOH Shigeru (80187195)

# of Collaborated Projects: 4 results

# of Collaborated Products: 62 results
3. SAITO Mitsuru (80400505)

# of Collaborated Projects: 2 results

# of Collaborated Products: 18 results
4. TSUCHIYA Norihiko (70282176)

# of Collaborated Projects: 2 results

# of Collaborated Products: 5 results
5. KOMATSUDA Atsushi (70272044)

# of Collaborated Projects: 2 results

# of Collaborated Products: 4 results
6. NIIOKA TAKENORI (20722276)

# of Collaborated Projects: 2 results

# of Collaborated Products: 17 results
7. Kagaya Hideaki

# of Collaborated Projects: 2 results

# of Collaborated Products: 8 results
8. SATO Kazuhiro (30436191)

# of Collaborated Projects: 1 results

# of Collaborated Products: 7 results
9. INOUE Takamitsu (60375243)

# of Collaborated Projects: 1 results

# of Collaborated Products: 17 results
10. NUMAKURA Kazuyuki (90566415)

# of Collaborated Projects: 1 results

# of Collaborated Products: 21 results
11. Shibata Hiroyuki (60393732)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
12. OKUYAMA SHIN (40543286)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
13. FUJIYAMA NOBUHIRO (90603275)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
14. 横山和明 (00647498)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
15. 大場雄介 (30333503)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
16. Abumiya Maiko

# of Collaborated Projects: 1 results

# of Collaborated Products: 9 results
17. Fujita Kazuma

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
18. YOKOTA Hayato

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
19. 西川博嘉

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
20. 柴山浩彦

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
21. 中山勝敏

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

MIURA MASATOMO 三浦 昌朋

MIURA Masatomo 三浦 昌朋

Research Projects

Research Products

Co-Researchers

Development of the new treatment technique utilizing the biomarkers of the molecular target drugs with the VEGFR2 inhibitory actionPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

TKI抵抗性CMLに対するエキソーム解析とFRET解析の統合による個別化治療の可能性

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of the treatment strategy for molecular target anticancer drugs to avoid serious side effectsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Personalized medicine of oral molecular-targeted anticancer drugs for elderly patientsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Influence of tacrolimus initial doing strategy based on the CYP3A5 polymorphisms on quantitative interstitial fibrosis, rejection rate, and long-term graft function in kidney transplant recipients.

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of a new treatment strategy using TDM for next generation anticancer drugPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Therapeutic drug management of the novel agents for multiple myeloma

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Do patients taking tacrolimus need to undergo CYP3A5 genotyping along with blood concentration monitoring?

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Therapeutic drug management of tyrosine kinase inhibitorPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Factors Increasing Interstitial Fibrosis and Its Reduction with Personalized Dosing of Immunosuppressive Drugs after Kidney Transplantation

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Clinical and Genomic Risk Factors for Early Onset of Chronic Allograft Nephropathy

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Book] 診断と治療のABC，慢性骨髄性白血病・骨髄増殖性腫瘍2016

Author(s)

Total Pages

Publisher

Data Source

[Book] ミコフェノール酸モフェチル.腎疾患治療マニュアル 2013-2014 腎と透析2013

Author(s)

Publisher

Data Source

MIURA MASATOMO 三浦昌朋

MIURA Masatomo 三浦昌朋